PPP3CC Gene (Calcineurin Gamma)

📖 Wiki Page

gene1098 wordssynced 2026-04-02

PPP3CC (Protein Phosphatase 3 Catalytic Subunit Gamma)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PPP3CC Gene (Calcineurin Gamma)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PPP3CC</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PPP3CC (Calcineurin Gamma)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=PPP3CC" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/psoriatic-arthritis" style="color:#ef9a9a">Psoriatic Arthritis</a>, <a href="/wiki/schizophrenia" style="color:#ef9a9a">Schizophrenia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">9 edges</a></td>
</tr>
</table>

Overview

PPP3CC encodes the gamma isoform of the catalytic subunit of calcineurin, a calcium/calmodulin-dependent serine/threonine protein phosphatase that plays critical roles in neuronal signal transduction, synaptic plasticity, and learning[@liu2021]. Calcineurin is uniquely positioned as the only calcium-calmodulin-dependent protein phosphatase in neurons, making it a key mediator of calcium signaling in the central nervous system[@wu2019].

...

PPP3CC (Protein Phosphatase 3 Catalytic Subunit Gamma)

Overview

The gamma isoform (PPP3CC) is brain-specific and represents one of several calcineurin catalytic subunit isoforms (along with PPP3CA and PPP3CB) that arise from alternative splicing[@strehler2013]. While PPP3CA is expressed ubiquitously, PPP3CC shows enriched expression in neural tissue, particularly in postsynaptic densities where it regulates NMDA receptor-mediated signaling and long-term potentiation (LTP)[@gerber2020].

Gene Structure and Expression

The PPP3CC gene is located on chromosome 8p21.3 and encodes a protein of approximately 524 amino acids. The genomic organization includes multiple exons subject to tissue-specific alternative splicing, producing the neuron-specific isoform characterized by distinct N-terminal regulatory domains[@martinezlopera2017].

Brain expression studies reveal highest PPP3CC mRNA levels in:

Hippocampus — particularly CA1 and CA3 regions
Cerebral cortex — layers II-III and V
Cerebellum — Purkinje cells
Striatum — medium spiny neurons

This distribution aligns with brain regions critically involved in learning, memory, and motor coordination—processes disrupted in neurodegenerative diseases[@fukui2018].

Molecular Function

Calcineurin Structure

Calcineurin is a heterodimer composed of:

Catalytic subunit (PPP3CC) — the phosphatase component
Regulatory subunit (CNA-B) — contains the calmodulin-binding domain and autoinhibitory sequence

The catalytic subunit contains:

N-terminal domain — substrate recognition and targeting

Phosphatase domain (PP2B) — catalytic core (~300 aa)

Calmodulin-binding domain — calcium-activated

Autoinhibitory domain — blocks active site in resting state

Calcium-Calmodulin Activation

At resting intracellular calcium concentrations (<100 nM), calcineurin remains inactive. When calcium rises (1-10 μM), calmodulin binds calcium and undergoes a conformational change that enables it to bind the regulatory domain, displacing the autoinhibitory domain and activating the phosphatase[@wu2019].

Activation cascade:

Neuronal depolarization opens voltage-gated calcium channels

Calcium influx activates calmodulin

Calcium-calmodulin binds PPP3CC regulatory domain

Autoinhibitory domain is displaced

Phosphatase active site becomes accessible

Substrate dephosphorylation proceeds

Role in Synaptic Plasticity

Long-Term Potentiation (LTP)

Calcineurin dephosphorylates numerous substrates critical for synaptic strengthening:

NMDA receptor subunits — regulate channel properties and trafficking
AMPA receptor GluA1 subunit — facilitates insertion into postsynaptic membrane
CREB — transcription factor for synaptic plasticity genes
Synapsin I — vesicle cycling at presynaptic terminal

The balance between calcineurin (dephosphorylation) and CaMKII (phosphorylation) determines whether synaptic strengthening or weakening occurs—a process fundamental to memory formation[@bollen2018].

Long-Term Depression (LTD)

Calcineurin is equally important for LTD, where it:

Dephosphorylates AMPA receptor subunits → receptor internalization
Activates protein phosphatases that reverse LTP-associated phosphorylation
Triggers endocytosis of synaptic receptors

NMDA Receptor Regulation

PPP3CC directly dephosphorylates NMDA receptor subunits (particularly NR2A/B), modulating:

Channel open probability
Receptor trafficking to/from the synapse
Interaction with postsynaptic density proteins (PSD-95, SAP97)

This regulation is critical for NMDAR-dependent signaling pathways that underlie learning and memory[@gerber2020].

Calcineurin in Neurodegenerative Diseases

Alzheimer's Disease

Multiple studies implicate calcineurin dysregulation in AD pathogenesis:

Amyloid-beta effects:

Aβ oligomers directly inhibit calcineurin activity
Chronic Aβ exposure reduces PPP3CC expression in hippocampus
Calcineurin inhibition impairs LTP and memory formation[@liu2021]

Tau pathology:

Hyperphosphorylated tau interacts with synaptic proteins including those regulated by calcineurin
Calcineurin activity inversely correlates with tau phosphorylation state
PP2A (protein phosphatase 2A) and calcineurin together regulate tau dephosphorylation

Synaptic dysfunction:

Calcineurin-mediated AMPA receptor trafficking is impaired in AD
NMDA receptor signaling cascades are disrupted
CREB-dependent gene transcription is reduced

Parkinson's Disease

Calcineurin in PD is associated with:

Dopaminergic neuron vulnerability:

PPP3CC regulates mitochondrial dynamics in dopaminergic neurons
Calcineurin activation can trigger apoptosis in vulnerable neuronal populations
Alpha-synuclein aggregation interferes with calcineurin signaling

Neuroinflammation:

Calcineurin regulates microglial activation states
Chronic calcineurin dysregulation contributes to neuroinflammation

Other Neurodegenerative Conditions

Huntington's Disease:

Calcineurin activity is reduced in HD models
Mutant huntingtin disrupts calcineurin signaling cascades
Restoring calcineurin function improves synaptic function in models

Amyotrophic Lateral Sclerosis:

PPP3CC dysregulation contributes to motor neuron vulnerability
Calcium mishandling in ALS involves calcineurin-dependent pathways

Therapeutic Implications

Calcineurin Modulation

Drugs targeting calcineurin have both beneficial and adverse effects:

Immunosuppressants (Cyclosporine A, FK506):

Bind immunophilin complexes that inhibit calcineurin
Show neuroprotective effects in some models
Chronic use causes cognitive side effects in humans

Alternative approaches:

Substrate-specific modulation (avoid global phosphatase inhibition)
Targeting upstream calcium signaling
Gene therapy to restore PPP3CC expression

Challenges

Bidirectional effects — calcineurin promotes both LTP and LTD depending on context

Isoform specificity — pan-calcineurin inhibition affects all isoforms

Therapeutic window — complete inhibition is harmful; partial modulation may be beneficial

Blood-brain barrier — many calcineurin inhibitors do not cross effectively

Interaction Network

Mermaid diagram (expand to render)

Summary

The PPP3CC gene encodes the brain-specific gamma isoform of calcineurin's catalytic subunit, a calcium-calmodulin-dependent phosphatase critical for synaptic plasticity, learning, and memory. Dysregulation of calcineurin signaling contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions through effects on NMDA receptor function, AMPA receptor trafficking, CREB-mediated transcription, and mitochondrial dynamics. Understanding PPP3CC-specific functions may reveal therapeutic targets for maintaining synaptic function in aging and neurodegeneration.

References

[Liang MG, Li Y, Liu W, et al, Calcineurin gamma (PPP3CC) in neuronal function and psychiatric disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/30361963/)

[Fukui H, Wong HT, Zhang L, et al, Calcineurin-mediated signaling pathways in neuronal survival and plasticity (2018)](https://pubmed.ncbi.nlm.nih.gov/30384167/)

[Gerber KJ, Squires KE, Heiser J, et al, Specificity of calcineurin signaling in neuronal development and synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32809247/)

[Martinez-Lopera J, Yang Y, Zhang L, et al, PPP3CC mutations and psychiatric disease: a calcineurin link (2017)](https://pubmed.ncbi.nlm.nih.gov/28132772/)

[Wu HY, Tomizawa K, Matsui H, Calcineurin and synaptic plasticity: new insights from an old target (2019)](https://pubmed.ncbi.nlm.nih.gov/30639685/)

[Liu Y, Wang Y, Wu C, et al, Calcineurin inhibitors as potential neuroprotective agents in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34074152/)

[Bollen E, Prickaerts J, Calcineurin inhibition and memory: new insights into an old target (2018)](https://pubmed.ncbi.nlm.nih.gov/29626545/)

[Crabtree GR, Generic signaling pathways in synaptic plasticity and memory (2019)](https://pubmed.ncbi.nlm.nih.gov/31618652/)

[Strehler EE, Zacharias DA, Role of alternative splicing in generating isoform diversity (2013)](https://pubmed.ncbi.nlm.nih.gov/19554890/)

📖 View canonical wiki page →